STLN — Starling Oncology, Inc.
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1799191 ·
Last close
$6.51
Market Cap
—
52W High
$7.13
52W Low
$2.32
ADV30
1,285,229
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 161,282,000 | 27,165,000 | -4,616,000 | -9,789,000 | 178,233,000 | 41,094,000 | 203,147,000 |
| Mar 2026 | 147,441,000 | 23,315,000 | -6,513,000 | -2,492,000 | 168,230,000 | 30,280,000 | 184,515,000 |
| Dec 2025 | 141,957,000 | 22,765,000 | -6,907,000 | -7,508,000 | 164,656,000 | 33,565,000 | 180,376,000 |
| Sep 2025 | 136,564,000 | 18,920,000 | -8,054,000 | -16,504,000 | 163,619,000 | 27,658,000 | 175,893,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$328,000
Investing CF
$-3,614,000
Financing CF
$14,088,000
CapEx
$-3,614,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.30
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-283,700,000
Inventory
$20,011,000
Receivables
$66,709,000
ST Investments
$0
EBIT TTM
$-28,664,000
Pretax Income TTM
$-36,293,000
Interest Exp TTM
$7,629,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 502,729,000 | -36,083,000 | -60,606,000 | 164,656,000 | 180,376,000 | -15,720,000 | -24,587,000 |
| Dec 2024 | 393,412,000 | -60,118,000 | -64,663,000 | 172,717,000 | 169,128,000 | 3,589,000 | -26,538,000 |
| Dec 2023 | 324,239,000 | -60,151,000 | -83,068,000 | 209,240,000 | 152,215,000 | 57,025,000 | -36,315,000 |
| Dec 2022 | 252,483,000 | -72,007,000 | 152,000 | 261,665,000 | 138,490,000 | 123,175,000 | -61,756,000 |
TTM Snapshot
Revenues TTM
$408,614,000
NetIncome TTM
$-71,396,000
OpCashFlow TTM
$0
Assets (Latest)
$164,656,000
Forward EPS
—
Max Pain — expiry 2026-11-20
max pain strike: $5.00 · spot: $6.32 · call oi: 51,910 · put oi: 1,326
Expected Move to 2026-11-20:
±$1.50
(23.73%) —
implied range
$4.82 –
$7.82
· ATM straddle on $6.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HCA | HCA Healthcare, Inc. | $93.45B | $431.63 | — |
| NTRA | Natera, Inc. | $59.75B | $414.52 | — |
| DGX | QUEST DIAGNOSTICS INC | $25.60B | $231.97 | — |
| LH | LABCORP HOLDINGS INC. | $25.04B | $308.81 | — |
| GH | Guardant Health, Inc. | $23.85B | $177.73 | — |
News headlines (Yahoo Finance, 1h cache)
Starling Oncology to Participate in Wells Fargo Healthcare Conference
2026-08-24 13:00 · Yahoo
The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates
2026-08-06 23:10 · Yahoo
Oncology Institute Q2 Earnings Call Highlights
2026-08-07 18:04 · Yahoo
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
2026-08-06 20:14 · Yahoo
Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale
2026-08-17 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.